Početna stranicaGNLX • NASDAQ
add
Genelux Corp
Preth. zaklj. cijena
2,48 $
Dnevni raspon
2,41 $ - 2,61 $
Godišnji raspon
1,60 $ - 5,89 $
Tržišna kapitalizacija
98,49 mil. USD
Prosječna količina
187,77 tis.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | ožu 2025.info | Godišnja promjena |
|---|---|---|
Prihod | — | — |
Operativni troškovi | 7,82 mil. | −3,78 % |
Neto dohodak | −7,49 mil. | 4,56 % |
Neto profitabilnost | — | — |
Zarada po dionici | −0,21 | 27,59 % |
EBITDA | −7,76 mil. | 3,41 % |
Efektivna porezna stopa | — | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | ožu 2025.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 35,10 mil. | 78,85 % |
Ukupna imovina | 38,98 mil. | 57,99 % |
Ukupne obveze | 9,14 mil. | −4,72 % |
Ukupni kapital | 29,85 mil. | — |
Dionice u optjecaju | 37,30 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 3,10 | — |
Povrat imovine | −53,02 % | — |
Povrat kapitala | −65,38 % | — |
Tok novca
Neto promjena novca
| (USD) | ožu 2025.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −7,49 mil. | 4,56 % |
Gotovina od poslovanja | −5,44 mil. | −24,83 % |
Gotovina iz ulaganja | 3,51 mil. | 307,51 % |
Gotovina iz financiranja | 9,57 mil. | 1.290,55 % |
Neto promjena novca | 7,64 mil. | 242,64 % |
Slobodan tok novca | −2,66 mil. | −103,16 % |
Više
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Osnovano
2001
Web-lokacija
Zaposlenici
24
